BioAge reported Phase 1 results for BGE-102, describing an 86% reduction in hs-CRP after three weeks at a 60 mg dose in people with obesity and elevated inflammation. The company said 87% of patients on that dose achieved hs-CRP levels below 2 mg/L, a threshold associated with lower cardiovascular complication risk. The update reinforces BioAge’s inflammation-centered strategy as pharmaceutical companies continue to test whether targeting inflammatory biology can translate into measurable clinical benefit beyond traditional risk-factor management. The company also highlighted similar magnitude effects at 120 mg, supporting a dose-response narrative. For the sector, the key issue will be whether the strong biomarker signal holds in larger, longer-duration studies and whether it correlates with changes in downstream clinical endpoints such as cardiovascular events and metabolic function.